Pricing Log in Create free account

BridgeBio Oncology Therapeutics, Inc (BBOT) vs SAB Biotherapeutics, Inc. (SABS)

BridgeBio Oncology Therapeutics, Inc and SAB Biotherapeutics, Inc. are both Biotechnology companies. BridgeBio Oncology Therapeutics, Inc and SAB Biotherapeutics, Inc. are of similar size ($236.5M and $235.7M). Across the 10 metrics below, SAB Biotherapeutics, Inc. leads on 7 and BridgeBio Oncology Therapeutics, Inc on 3.

Valuation

Metric BBOT SABS Biotechnology median
P/E n/m n/m 8.50
P/S n/m 123.99 9.71
P/B 0.70 0.94 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 62.79 9.21
Earnings yield (97.87%) (25.30%) (33.15%)
Free cash flow yield (67.14%) (28.47%) (25.50%)

Profitability

Metric BBOT SABS Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (252.10%) (19.21%) (56.36%)
Return on assets (96.69%) (16.24%) (48.04%)
Return on invested capital (127.66%) (38.97%) 0.00%

Growth

Metric BBOT SABS Biotechnology median
Revenue growth (TTM) — (60.26%) 6.02%
EPS growth (last fiscal year) 99.93% 78.53% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — (26.69%) 0.00%

Health

Metric BBOT SABS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 4.69 9.22 4.72
Net debt to EBITDA 2.93 2.03 0.96

Dividend

Metric BBOT SABS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BBOT SABS Biotechnology median
Market cap 236.52m 235.66m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack